Medication use and polypharmacy in patients referred to a tertiary gastroenterology practice

Chris-Olaiya, Abimbola; Palmer, William C.; Stancampiano, Fernando; Lacy, Brian E.; Heckman, Michael G.; Chirilă, Răzvan M.; Nikpour, Naveed; McLeod, Ethan; Ryan, Taylor; Maillis, Alex; Vargas, Emily; Bouras, Ernest P.

doi:10.2478/rjim-2020-0016

Cited by 3 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Al-Hashar et al [ 7 ] in Oman and Al-Amin et al [ 8 ] in Bangladesh have shown that among CVDs patients, drugs related to the alimentary tract and metabolism were the most frequently used after cardiovascular medications. One possible explanation for this may be the use of different medicines in patients with CVDs which makes it inevitable to use antacid drugs to control the GI upset caused by simultaneous consumption of other medications [ 39 ].…”

Section: Discussionmentioning

confidence: 99%

Population-based pattern of medication use and prevalence of polypharmacy among patients with cardiovascular diseases: results of the Pars cohort study from Iran

Mohsenzadeh

Ardekani

Mohammadi

et al. 2022

BMC Cardiovasc Disord

View full text Add to dashboard Cite

Background Polypharmacy in patients with cardiovascular diseases (CVDs) has been linked to several adverse outcomes. This study aimed to investigate the pattern of medication use and prevalence of polypharmacy among CVDs patients in Iran. Method We used the baseline data of the Pars cohort study (PCS). The participants were asked to bring their medication bags; then, the medications were classified using the Anatomical Therapeutic Chemical classification. Polypharmacy was defined as using five or more medications concurrently. Poisson regression modeling was applied. The adjusted prevalence ratios (PR) and its 95% confidence interval (CI) were estimated. Results Totally, 9262 participants were enrolled in the PCS, of whom 961 had CVDs. The prevalence of polypharmacy in participants with and without CVDs was 38.9% and 7.1%, respectively. The highest prevalence of polypharmacy (51.5%) was among obese patients. Abnormal waist-hip ratio (PR: 2.79; 95% CI 1.57–4.94), high socioeconomic status (PR: 1.65; 95% CI 1.07–2.54), tobacco-smoking (PR: 1.35; 95% CI 1.00–1.81), patients with more than three co-morbidities (PR: 1.41; 95% CI 1.30–1.53), high physical activity (PR: 0.66; 95% CI 0.45–0.95), use of opiate ever (PR: 0.46; 95% CI 0.26–0.82), and healthy overweight subjects (PR: 0.22; 95% CI 0.12–0.39) were associated with polypharmacy. Cardiovascular drugs (76.1%), drugs acting on blood and blood-forming organs (50.4%), and alimentary tract and metabolism drugs (33.9%) were the most frequently used drugs. Agents acting on the renin-angiotensin system were the mostly used cardiovascular system drugs among men and those above 60 years old, while beta-blocking agents were mostly prevalent among cardiovascular system drugs in women with CVDs. Conclusion Given the high prevalence of polypharmacy among CVDs patients, and subsequent complications, programs to educate both physicians and patients to prevent this issue is crucial.

show abstract

Section: Discussionmentioning

confidence: 99%

Population-based pattern of medication use and prevalence of polypharmacy among patients with cardiovascular diseases: results of the Pars cohort study from Iran

Mohsenzadeh

Ardekani

Mohammadi

et al. 2022

BMC Cardiovasc Disord

View full text Add to dashboard Cite

show abstract

“… 86 Other common gastrointestinal symptoms including dyspepsia are also frequently associated with polypharmacy. 87 , 88 …”

Section: Polypharmacy and Medication Side Effectsmentioning

confidence: 99%

Systemic Disease Associations with Disorders of Gut–Brain Interaction and Gastrointestinal Transit: A Review

Moudgal¹,

Schultz²,

Shah³

2021

CEG

View full text Add to dashboard Cite

Functional gastrointestinal disorders (FGID) are now classified within the Rome IV framework as disorders of gut–brain interaction (DGBI). Disorders of gastrointestinal transit (as defined by abnormalities on contemporary gastrointestinal motility testing) frequently are associated with symptoms that are also characteristic of DGBIs. In this narrative review, we outline a non-inclusive set of systemic diseases or risk factors that have been classically associated with DGBIs and disorders of gastrointestinal transit; these include diabetes mellitus, paraneoplastic syndromes, surgery, Parkinson’s disease, systemic sclerosis, endocrinopathies, polypharmacy, and post-infectious syndromes.

show abstract

Worldwide Prevalence of Polypharmacy: A Systematic Review

Januário,

Mafra,

de Souza Silva

et al. 2023

CDM

View full text Add to dashboard Cite

Introduction: The present study has compiled the prevalence of polypharmacy worldwide and assessed the prevalence of polypharmacy in different populations, including community-dwelling individuals, hospitalized patients, and institutionalized patients. Methods: This systematic review was conducted and reported according to the guidelines outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement. A systematic search of electronic databases, including PubMed, Web of Science, and Scielo, was performed in March 2021 without any date and language restrictions. Combinations of the following keywords were used for the search strategy: polypharmacy OR multiple medications OR multiple medicines OR multiple drug AND prevalence. Based on the search and inclusion criteria, two hundred and eight studies (73,076,167 individuals) were selected for inclusion in the systematic review. It was observed that there is a wide variation in the prevalence of polypharmacy between studies. Results: The prevalence of polypharmacy was found to be 30.2%, 61.7%, and 56.9% for community-dwelling individuals, hospitalized patients, and institutionalized patients, respectively. Conclusion: Based on the analyses, this systematic review has demonstrated a wide variation in the prevalence of polypharmacy between studies and countries and a high prevalence of polypharmacy in institutionalized and hospitalized patients.

show abstract

Medication use and polypharmacy in patients referred to a tertiary gastroenterology practice

Cited by 3 publications

References 18 publications

Population-based pattern of medication use and prevalence of polypharmacy among patients with cardiovascular diseases: results of the Pars cohort study from Iran

Population-based pattern of medication use and prevalence of polypharmacy among patients with cardiovascular diseases: results of the Pars cohort study from Iran

Systemic Disease Associations with Disorders of Gut–Brain Interaction and Gastrointestinal Transit: A Review

Worldwide Prevalence of Polypharmacy: A Systematic Review

Contact Info

Product

Resources

About